ORIGINAL RESEARCH
Accepted on 07 May 2025
Immune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma
doi 10.3389/fphar.2025.1577232
- Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Multi-omics Application in Exploring Potential Biomarkers Targeting Resistance of Anti-Cancer Drugs, Volume II
Multi-omics Application in Exploring Potential Biomarkers Targeting Resistance of Anti-Cancer Drugs, Volume II
1,025
Total downloads
5,789
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 28 Apr 2025
Bioinformatics analysis across pan-cancer and experimental validation in hepatocellular carcinoma revealed the oncogenic role of SF3B6
doi 10.3389/fphar.2025.1516534
- 791 views
ORIGINAL RESEARCH
Published on 17 Apr 2025
LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis
doi 10.3389/fphar.2025.1592846
- 767 views
ORIGINAL RESEARCH
Published on 15 Apr 2025
Integrative analysis of m6A-SNPs and single-cell RNA sequencing reveals key drivers of endocrine combined with CDK4/6 inhibitor therapy resistance in ER+ breast cancer
doi 10.3389/fphar.2025.1590363
- 743 views
ORIGINAL RESEARCH
Published on 18 Feb 2025
ASF1B promotes gastric cancer progression by modulating H2AC20 and activating PI3K/AKT and ERK1/2 pathways
doi 10.3389/fphar.2025.1533257
- 729 views
ORIGINAL RESEARCH
Published on 04 Feb 2025
TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response
doi 10.3389/fphar.2025.1517887
- 783 views
Published in
Frontiers in Pharmacology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: